Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on precision medicines for oncology and genetically defined conditions. Its pipeline centers on oral small-molecule programs that target fibroblast growth factor receptor (FGFR) biology, including dabogratinib and TYRA-200, supported by its proprietary SNÅP drug-design platform.

14.67

14.67

— Tyra Biosciences, Inc.
%
Clinical-stage drug candidates0% Oral small-molecule programs in clinical development for FGFR-driven cancers and related conditions.
Discovery platform0% SNÅP is the internal drug-design platform used to generate and optimize new candidates.
Preclinical pipeline0% Undisclosed early-stage programs focused on FGFR biology and other precision-oncology targets.

Tyra Biosciences does not currently sell commercial products; its near-term 'customers' are clinical trial...

  • Clinical trial patientsprimary

    Patients with FGFR-altered cancers or genetic conditions enrolled in studies of TYRA-200, TYRA-430, and dabogratinib.

  • Clinical investigators and trial sitesprimary

    Hospitals and research centers that recruit patients, administer study drugs, and generate safety/efficacy data.

  • Future oncology prescriberssecondary

    Oncologists who would prescribe approved FGFR-targeted therapies for urothelial cancer, ICC, HCC, and other tumors.

  • Future specialty-care physicianssecondary

    Physicians treating skeletal dysplasia who could use dabogratinib if it reaches that indication.

Tyra Biosciences is headquartered in the United States and conducts development work through a clinical-trial network...

  • •Headquartered in the United States
  • •Clinical development is run through multicenter trial sites
  • •Trial geography can expand with patient-enrollment needs
  • •Future commercialization would depend on major market approvals
  • •Potential manufacturing and supply-chain exposure may include China

Tyra Biosciences is building a wholly owned pipeline around FGFR biology, using its SNÅP platform to design more...

01
Advance lead clinical programsshort-term

Clinical proof-of-concept is the main value driver for a pre-revenue biotech.

02
Differentiate through selectivity and resistance coveragemedium-term

Better selectivity and resistance handling can improve efficacy and tolerability versus older FGFR drugs.

03
Expand the SNÅP discovery enginelong-term

A productive platform can create multiple shots on goal beyond the current pipeline.

Tyra Biosciences faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory delays, and...

critical

Clinical development failure

The company has no approved products, so value depends on positive trial readouts and tolerability.

Scope
dabogratinib, TYRA-200, TYRA-430
Materiality
high
high

Regulatory and approval risk

Even promising data may not translate into marketing approval or label breadth.

Scope
all pipeline programs
Materiality
high
high

Competitive displacement

Other FGFR and oncology therapies may be more effective, safer, or faster to market.

Scope
FGFR-targeted oncology
Materiality
high
medium

Third-party manufacturing and CRO dependence

The company relies on external partners for clinical supply and trial execution.

Scope
clinical and preclinical programs
Materiality
medium
medium

China sourcing and trade restrictions

Use of foreign contract manufacturers can be affected by tariffs, sanctions, and U.S. restrictions.

Scope
manufacturing supply chain
Materiality
medium
Accrued research and development expenses
Can move quarterly operating expense and liabilities
Stock-based compensation
Affects operating loss and equity dilution
Marketable securities valuation and interest income
Affects other income and liquidity presentation

Damora Therapeutics, Inc.

DMRA · Pharmaceutical Preparations

Aura Biosciences, Inc.

AURA · Biological Products, (No Diagnostic Substances)

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Forte Biosciences, Inc.

FBRX · Pharmaceutical Preparations

Protara Therapeutics, Inc.

TARA · Biological Products, (No Diagnostic Substances)

Cogent Biosciences, Inc.

COGT · Pharmaceutical Preparations

: 29/04/2026